Zobrazit v EDS

Electronic data sources for drug utilization research and healthcare decision-making in Mexico.

Uloženo v:
Podrobná bibliografie
Název: Electronic data sources for drug utilization research and healthcare decision-making in Mexico.
Autoři: Santa-Ana-Tellez Y; Division of Pharmacoepidemiology & Clinical Pharmacology, Utrecht Institute of Pharmaceutical Sciences, Utrecht, The Netherlands., Dreser Mansilla A; Centre for Health Systems Research, National Institute of Public Health, Cuernavaca, Mexico. anahi.dreser@insp.mx., Castro Pastrana LI; Department of Chemical and Biological Sciences, School of Sciences, Universidad de las Américas Puebla, San Andrés Cholula, Mexico., Salas M; Bayer Pharmaceuticals, Whippany, NJ, USA.; Center for Clinical Epidemiology and Biostatistics/Center for Pharmacoepidemiology Research and Training, University of Pennsylvania, Philadelphia, PA, USA.; Rutgers Center for Pharmacoepidemiology and Treatment Science (PETS), Rutgers University, New Brunswick, NJ, USA., Sánchez Salgado JC; Hypermedic MX, Mexico City, Mexico., Gómez-Galicia D; Pharmacy faculty, Universidad Autónoma del Estado de Morelos, Cuernavaca, Mexico., Freitas Leal L; Centre de Recherche Azrieli du CHU Sainte-Justine - Unité de recherche sur les Médicaments et la Grossesse, Montréal, Québec, Canada., Cruz Lopes L; Pharmaceutical Science Graduate Course, University of Sorocaba, UNISO, São Paulo, Brazil.
Zdroj: BMC health services research [BMC Health Serv Res] 2025 Sep 26; Vol. 25 (1), pp. 1214. Date of Electronic Publication: 2025 Sep 26.
Způsob vydávání: Journal Article
Jazyk: English
Informace o časopise: Publisher: BioMed Central Country of Publication: England NLM ID: 101088677 Publication Model: Electronic Cited Medium: Internet ISSN: 1472-6963 (Electronic) Linking ISSN: 14726963 NLM ISO Abbreviation: BMC Health Serv Res Subsets: MEDLINE
Imprint Name(s): Original Publication: London : BioMed Central, [2001-
Výrazy ze slovníku MeSH: Drug Utilization*/statistics & numerical data , Decision Making* , Pharmacoepidemiology* , Databases, Factual*, Mexico ; Humans ; Information Sources
Abstrakt: Competing Interests: Declarations. Ethics approval and consent to participate: Not applicable. Consent for publication: Not applicable. Competing interests: The authors declare no competing interests.
Background: Understanding drug utilization is essential for informed decision-making in national healthcare and for enabling comparisons across countries. In Mexico, the limited research in this field may be attributed to the lack of awareness and accessibility of existing data sources. Addressing this gap requires a comprehensive inventory of data sources for Drug Utilization Research (DUR). The purpose of this study was to develop an inventory of electronic data sources available in Mexico for DUR, outlining their characteristics, strengths, and limitations.
Methods: From 2019 to 2024, specialists in pharmacoepidemiology and healthcare systems research conducted online searches for DUR data sources, including official websites of the Mexican government and public health institutions. A literature review was also performed for country-specific data sources in articles published between 2000 and 2023. Data sources were independently searched, screened, and selected by independent reviewers, with disagreements resolved through consensus. A descriptive analysis of selected databases was conducted, focusing on accessibility, geographical coverage, data aggregation level, health sector type, data source type, and setting.
Results: The analysis included twenty data sources, of which only four were publicly available. These databases offer insights into various aspects of drug utilization, primarily owned by social security institutions (twelve). Only four contain data from the private healthcare sector. Regarding data source type, five focused on procurement, twelve on prescription, two on pharmacovigilance, and one on drug disposal.
Conclusions: Mexico faces notable challenges in accessible data for DUR especially in non-social security institutions and the private sector. This study underscores the urgent need to improve healthcare data accessibility and research in Mexico, to drive evidence-informed decision-making regarding medicines utilization.
(© 2025. The Author(s).)
References: Salud Publica Mex. 2022 Aug 26;64(5, sept-oct):522-529. (PMID: 36130337)
Health Syst Reform. 2020 Jan 1;6(1):1-11. (PMID: 32568597)
Pharmaceut Med. 2023 Nov;37(6):425-437. (PMID: 37804414)
Salud Publica Mex. 2010 Jan-Feb;52(1):30-8. (PMID: 20464251)
Eur J Clin Pharmacol. 2013 May;69 Suppl 1:43-51. (PMID: 23640187)
Antimicrob Agents Chemother. 2015 Jan;59(1):105-10. (PMID: 25313222)
Salud Publica Mex. 2015;57 Suppl 2:s119-26. (PMID: 26545127)
Drug Saf. 2012 Oct 1;35(10):837-44. (PMID: 22924896)
PLoS One. 2015 Sep 25;10(9):e0136823. (PMID: 26407158)
J Am Med Inform Assoc. 2013 Mar-Apr;20(2):238-44. (PMID: 23019239)
Lancet Infect Dis. 2014 Aug;14(8):742-750. (PMID: 25022435)
Value Health Reg Issues. 2019 Dec;20:129-135. (PMID: 31374426)
Health Policy Plan. 2020 Apr 1;35(3):291-301. (PMID: 31872242)
Health Policy Plan. 2016 Nov;31(9):1291-6. (PMID: 27229872)
Res Social Adm Pharm. 2006 Mar;2(1):22-37. (PMID: 17138499)
Rev Panam Salud Publica. 2010 Mar;27(3):219-25. (PMID: 20414511)
BMC Med Inform Decis Mak. 2012 Jun 06;12:50. (PMID: 22672471)
Front Pharmacol. 2023 Jan 17;13:1047946. (PMID: 36733379)
Trop Med Int Health. 2013 Jun;18(6):665-73. (PMID: 23551290)
Adv Pharmacol Pharm Sci. 2023 Nov 21;2023:5555274. (PMID: 38035129)
Salud Publica Mex. 2015;57 Suppl 2:s171-82. (PMID: 26545133)
BMC Pregnancy Childbirth. 2014 May 16;14:168. (PMID: 24885103)
Int J Qual Health Care. 2015 Apr;27(2):125-31. (PMID: 25681517)
Salud Colect. 2021 May 27;17:e3339. (PMID: 34105332)
EXCLI J. 2021 Feb 04;20:199-222. (PMID: 33628159)
Lancet. 2009 Jan 17;373(9659):240-9. (PMID: 19042012)
Health Syst Reform. 2022 Jan 1;8(1):2084221. (PMID: 35723656)
Health Syst Transit. 2020 Apr;22(2):1-222. (PMID: 33527902)
Biol Pharm Bull. 2023;46(6):781-787. (PMID: 37258142)
Salud Publica Mex. 2023 Apr 21;65(3):305-306. (PMID: 38060869)
J Hypertens. 2013 Aug;31(8):1714-23. (PMID: 23673349)
Bol Med Hosp Infant Mex. 2015 Jul - Aug;72(4):235-241. (PMID: 29421142)
Pharmacoepidemiol Drug Saf. 2016 Jan;25(1):16-25. (PMID: 26486230)
Pharmacoepidemiol Drug Saf. 2022 Mar;31(3):343-352. (PMID: 34957616)
Health Serv Res. 2016 Aug;51(4):1323-46. (PMID: 27417264)
BMJ Open. 2014 May 22;4(5):e004669. (PMID: 24852298)
Salud Publica Mex. 2016 Nov-Dec;58(6):708-716. (PMID: 28225947)
Pharmacoepidemiol Drug Saf. 2020 Nov;29(11):1353-1363. (PMID: 32419226)
PLoS One. 2013 Oct 16;8(10):e75550. (PMID: 24146761)
Int J Public Health. 2014 Oct;59(5):877-87. (PMID: 24875352)
Contributed Indexing: Keywords: Data sources; Drug utilization research; Health information systems; Mexico; Pharmacoepidemiology
Entry Date(s): Date Created: 20250927 Date Completed: 20250927 Latest Revision: 20250930
Update Code: 20250930
PubMed Central ID: PMC12466055
DOI: 10.1186/s12913-025-13216-4
PMID: 41013600
Databáze: MEDLINE
Popis
Abstrakt:Competing Interests: Declarations. Ethics approval and consent to participate: Not applicable. Consent for publication: Not applicable. Competing interests: The authors declare no competing interests.<br />Background: Understanding drug utilization is essential for informed decision-making in national healthcare and for enabling comparisons across countries. In Mexico, the limited research in this field may be attributed to the lack of awareness and accessibility of existing data sources. Addressing this gap requires a comprehensive inventory of data sources for Drug Utilization Research (DUR). The purpose of this study was to develop an inventory of electronic data sources available in Mexico for DUR, outlining their characteristics, strengths, and limitations.<br />Methods: From 2019 to 2024, specialists in pharmacoepidemiology and healthcare systems research conducted online searches for DUR data sources, including official websites of the Mexican government and public health institutions. A literature review was also performed for country-specific data sources in articles published between 2000 and 2023. Data sources were independently searched, screened, and selected by independent reviewers, with disagreements resolved through consensus. A descriptive analysis of selected databases was conducted, focusing on accessibility, geographical coverage, data aggregation level, health sector type, data source type, and setting.<br />Results: The analysis included twenty data sources, of which only four were publicly available. These databases offer insights into various aspects of drug utilization, primarily owned by social security institutions (twelve). Only four contain data from the private healthcare sector. Regarding data source type, five focused on procurement, twelve on prescription, two on pharmacovigilance, and one on drug disposal.<br />Conclusions: Mexico faces notable challenges in accessible data for DUR especially in non-social security institutions and the private sector. This study underscores the urgent need to improve healthcare data accessibility and research in Mexico, to drive evidence-informed decision-making regarding medicines utilization.<br /> (© 2025. The Author(s).)
ISSN:1472-6963
DOI:10.1186/s12913-025-13216-4